M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112742 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Shizhi He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University. Dongcheng District, Beijing, China; Ke…. Hauptthemen laut MEDLINE: Exosomes, Homeodomain Proteins, Laryngeal Neoplasms, Macrophages. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Tongren Hospital, Ministry of Education of the People's Republic of China, Capital Health Research and Development of Special Fund.
Abstract (Originalsprache)
This study investigates the role of M2-exo-mediated HOXC13-AS in laryngeal squamous cell carcinoma (LSCC) by examining its transmission to tumor microenvironment (TME) macrophages. Exosomes from M2 macrophages were isolated and characterized using transmission electron microscopy, nanoparticle tracer analysis and western blot. Expression of HOXC13-AS, miR-485-5p, IGF2BP2, and PD-L1 was analyzed. Different interventions on LSCC cell function and immune escape were detected using molecular biological techniques. The study found that elevated HOXC13-AS were present in LSCC, and M2-exo expression was significantly increased in LSCC cells. Silencing HOXC13-AS in M2-exo inhibited LSCC malignant progression and immune escape in vivo and in vitro. M2-exo-mediated HOXC13-AS also regulated IGF2BP2 expression, impacting cellular biological function and immune escape process. The study concludes that M2-exo-mediated HOXC13-AS promotes LSCC malignancy and immune escape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University. Dongcheng District, Beijing, China; Key Laboratory of Otorhinolaryngology Head and Neck Surgery (Capital Med…
Förderung
- Beijing Tongren Hospital
- Ministry of Education of the People's Republic of China
- Capital Health Research and Development of Special Fund
Zitieren
APA
He, S., He, Y., Zhu, S., Wang, R., Liu, S., Wang, L., Shen, X., Li, X., Chen, S., & Fang, J. (2024). M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112742
Vancouver
He S, He Y, Zhu S, Wang R, Liu S, Wang L, et al. M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112742
BibTeX
@article{He2024,
author = {He, Shizhi and He, Yurong and Zhu, Siyu and Wang, Ru and Liu, Shaokun and Wang, Lingwa and Shen, Xixi and Li, Xinyu and Chen, Shaoshi and Fang, Jugao},
title = {M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112742}
}
EUVIMED